Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Reilly Website

Karlyne M. Reilly, Ph.D.

Selected Publications

1)  Devkota KP, Wilson JA, Henrich CJ, McMahon JB, Reilly KM, Beutler JA.
Compounds from Simarouba berteroana which inhibit proliferation of NF1-defective cancer cells.
Phytochem Lett. 7: 42-45, 2014.
[Journal]
2)  Lockett S, Verma C, Brafman A, Gudla P, Nandy K, Mimaki Y, Fuchs PL, Jaja J, Reilly KM, Beutler J, Turbyville TJ.
Quantitative analysis of F-actin redistribution in astrocytoma cells treated with candidate pharmaceuticals.
Cytometry A. 2014.
[Journal]
3)  Reilly K.
Abate-Shen C, Politi K, Chodosh L, Olive K, eds.
Controlling Genetic Background in Crosses of Mouse Models of Cancer. In: Mouse Models of Cancer.
Cold Spring Harbor: Cold Spring Harbor Protocols; 2013. In Press. [Book Chapter]
4)  Reilly K.
Abate-Shen C, Politi K, Chodosh L, Olive K, eds.
The Effect of Genetic Background of Mouse Models of Human Cancer: Friend or Foe?. In: Mouse Models of Cancer.
Cold Spring Harbor: Cold Spring Harbor Protocols; 2013. In Press. [Book Chapter]
5)  Reilly K.
Abate-Shen C, Politi K, Chodosh L, Olive K, eds.
Using the Collaborative Cross to Study the Role of Genetic Diversity in Cancer-Related Phenotypes. In: Mouse Models of Cancer.
Cold Spring Harbor: Cold Spring Harbor Protocols; 2013. In Press. [Book Chapter]
6)  Jones G, Reilly K.
Upadhyaya M, Cooper D, eds.
Dissection of Complex Genetic and Epigenetic Interactions Underlying NF1 Cancer Susceptibility Using Mouse Models. In: Neurofirbomatosis Type 1.
Berlin: Springer-Verlag; 2013. In Press. [Book Chapter]
7)  Reilly KM.
Extending the convergence of canonical WNT signaling and classic cancer pathways for treatment of malignant peripheral nerve sheath tumors.
Cancer Discov. 3: 610-2, 2013.
[Journal]
8)  Zemp FJ, McKenzie BA, Lun X, Maxwell L, Reilly KM, McFadden G, Yong VW, Forsyth PA.
Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.
PLoS ONE. 8: e65801, 2013.
[Journal]
9)  Devkota KP, Wilson J, Henrich CJ, McMahon JB, Reilly KM, Beutler JA.
Isobutylhydroxyamides from the pericarp of Nepalese Zanthoxylum armatum inhibit NF1-defective tumor cell line growth.
J. Nat. Prod. 76: 59-63, 2013.
[Journal]
10)  Amlin-Van Schaick JC, Kim S, Difabio C, Lee MH, Broman KW, Reilly KM.
Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12.
Neuro-oncology. 14: 160-74, 2012.
[Journal]
11)  Simmons JK, Amlin-Van Schaick JC, Geiger TR, Reilly K, Hunter K, Mock BA.
Mouse genetics 2011: meeting report.
Mamm. Genome. 23: 225-31, 2012.
[Journal]
12)  Huson SM, Acosta MT, Belzberg AJ, Bernards A, Chernoff J, Cichowski K, Gareth Evans D, Ferner RE, Giovannini M, Korf BR, Listernick R, North KN, Packer RJ, Parada LF, Peltonen J, Ramesh V, Reilly KM, Risner JW, Schorry EK, Upadhyaya M, Viskochil DH, Zhu Y, Hunter-Schaedle K, Giancotti FG.
Back to the future: proceedings from the 2010 NF Conference.
Am. J. Med. Genet. A. 155A: 307-21, 2011.
[Journal]
13)  Gürsel DB, Connell-Albert YS, Tuskan RG, Anastassiadis T, Walrath JC, Hawes JJ, Amlin-Van Schaick JC, Reilly KM.
Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.
Neuro-oncology. 13: 610-21, 2011.
[Journal]
14)  Amlin-Van Schaick J, Kim S, Broman KW, Reilly KM.
Scram1 is a modifier of spinal cord resistance for astrocytoma on mouse Chr 5.
Mamm Genome. 23: 277-85, 2011.
[Journal]
15)  Hawes JJ, Reilly KM.
Bioluminescent approaches for measuring tumor growth in a mouse model of neurofibromatosis.
Toxicol Pathol. 38: 123-30, 2010.
[Journal]
16)  Pemov A, Park C, Reilly KM, Stewart DR.
Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiency.
BMC Genomics. 11: 194, 2010.
[Journal]
17)  Walrath JC, Hawes JJ, Van Dyke T, Reilly KM.
Genetically engineered mouse models in cancer research.
Adv. Cancer Res. 106: 113-64, 2010.
[Journal]
18)  Turbyville TJ, Gürsel DB, Tuskan RG, Walrath JC, Lipschultz CA, Lockett SJ, Wiemer DF, Beutler JA, Reilly KM.
Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner.
Mol. Cancer Ther. 9: 1234-43, 2010.
[Journal]
19)  Banerjee S, Byrd JN, Gianino SM, Harpstrite SE, Rodriguez FJ, Tuskan RG, Reilly KM, Piwnica-Worms DR, Gutmann DH.
The Neurofibromatosis Type 1 Tumor Suppressor Controls Cell Growth by Regulating Signal Transducer and Activator of Transcription-3 Activity In vitro and In vivo.
Cancer Res. 70: 1356-66, 2010.
[Journal]
20)  Reilly KM.
Van Meir EG, eds.
The Nf1-/+;Trp53-/+cis mouse model of anaplastic astrocytoma and secondary glioblastoma: Dissecting genetic susceptibility to brain cancer. In: CNS cancer, Models, Prognostic Factors and Targets.
New York: Humana Press; 2009. p. 93-118 [Book Chapter]
21)  Reilly KM.
Brain tumor susceptibility: the role of genetic factors and uses of mouse models to unravel risk.
Brain Pathol. 19: 121-31, 2009.
[Journal]
22)  Walrath JC, Fox K, Truffer E, Gregory Alvord W, Quiñones OA, Reilly KM.
Chr 19(A/J) modifies tumor resistance in a sex- and parent-of-origin-specific manner.
Mamm. Genome. 20: 214-23, 2009.
[Journal]
23)  Reilly K.
Neurofibromatosis and lessons for the war on cancer.
EMBO Mol Med. 1: 198-200, 2009.
Full Text Article. [Journal]
24)  Reilly KM, Van Dyke T.
It takes a (dysfunctional) village to raise a tumor.
Cell. 135: 408-10, 2008.
[Journal]
25)  Hawes JJ, Nerva JD, Reilly KM.
Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds.
J Biomol Screen. 13: 795-803, 2008.
[Journal]
26)  Tuskan RG, Tsang S, Sun Z, Baer J, Rozenblum E, Wu X, Munroe DJ, Reilly KM.
Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows balanced expression from the maternal and paternal chromosomes and strain-specific variation in expression levels.
Epigenetics. 3: 43-50, 2008.
[Journal]
27)  Reilly KM, Rubin JB, Gilbertson RJ, Garbow JR, Roussel MF, Gutmann DH.
Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium nervous system tumors workshop.
Cancer Res. 68: 5508-11, 2008.
[Journal]
28)  Hawes JJ, Tuskan RG, Reilly KM.
Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.
Neurogenetics. 8: 121-30, 2007.
[Journal]
29)  Reilly KM, Broman KW, Bronson RT, Tsang S, Loisel DA, Christy ES, Sun Z, Diehl J, Munroe DJ, Tuskan RG.
An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model.
Cancer Res. 66: 62-8, 2006.
[Journal]
30)  Gursel D, Reilly K.
Models of Astrocytoma.
Drug Discovery Today: Disease Models. 2: 77-83, 2005.
Full Text Article. [Journal]
31)  Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT, Burns DK, Cervera P, McLaughlin ME, Reifenberger G, Schmale MC, MacCollin M, Chao RC, Cichowski K, Kalamarides M, Messerli SM, McClatchey AI, Niwa-Kawakita M, Ratner N, Reilly KM, Zhu Y, Giovannini M.
Comparative pathology of nerve sheath tumors in mouse models and humans.
Cancer Res. 64: 3718-24, 2004.
[Journal]
32)  Reilly KM, Tuskan RG, Christy E, Loisel DA, Ledger J, Bronson RT, Smith CD, Tsang S, Munroe DJ, Jacks T.
Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects.
Proc Natl Acad Sci U S A. 101: 13008-13, 2004.
[Journal]
33)  Reilly KM.
The Importance of Genome Architecture in Cancer Susceptibility: Location, Location, Location.
Cell Cycle. 3: 1378-82, 2004.
[Journal]
34)  Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H.
Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors.
J Transl Med. 2: 40, 2004.
[Journal]
35)  Weiss WA, Israel M, Cobbs C, Holland E, James CD, Louis DN, Marks C, McClatchey AI, Roberts T, Van Dyke T, Wetmore C, Chiu IM, Giovannini M, Guha A, Higgins RJ, Marino S, Radovanovic I, Reilly K, Aldape K.
Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum.
Oncogene. 21: 7453-63, 2002.
[Journal]
36)  Reilly KM, Jacks T.
Genetically engineered mouse models of astrocytoma: GEMs in the rough.
Semin Cancer Biol. 11: 177-191, 2001.
[Journal]
37)  Bajenaru ML, Donahoe J, Corral T, Reilly KM, Brophy S, Pellicer A, Gutmann DH.
Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes.
Glia. 33: 314-323, 2001.
[Journal]
38)  Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T.
Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.
Nat Genet. 26: 109-113, 2000.
[Journal]
39)  Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T.
Mouse models of tumor development in neurofibromatosis type 1.
Science. 286: 2172-2176, 1999.
[Journal]
40)  Reilly KM, Melton DA.
Short-range signaling by candidate morphogens of the TGF beta family and evidence for a relay mechanism of induction.
Cell. 86: 743-54, 1996.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 8/11/2014.